Toggle navigation
Upcoming Events
Terms & Conditions
Privacy Policy
Contact Us
Step 1 of 5
20%
Please help us to improve our services with this quick questionnaire. Kindly take some time to fill out the following information before you continue.
Country of residence:
*
Profession
Physician
Physician, Fellow-in-Training
Cardiovascular Technologist
Clinical Focus
Clinical Cardiology
Interventional Cardiology
Primary Care Medicine
Years of experience in cardiology
*
0 - 5
6 - 10
11 - 20
21 - 30
31+
On average, how many patients do you provide direct cardiovascular care to in a week?
*
Please indicate your level of agreement with the following statements.
The content was clinically relevant to my patients and clinical practice.
Strongly Disagree
Disagree
Undecided
Agree
Strongly Agree
The design and format supported my learning.
Strongly Disagree
Disagree
Undecided
Agree
Strongly Agree
The length of the conference was appropriate (not too long or too short).
Strongly Disagree
Disagree
Undecided
Agree
Strongly Agree
My learning from this conference will enhance my professional effectiveness
Strongly Disagree
Disagree
Undecided
Agree
Strongly Agree
Overall, I am satisfied with this conference.
Strongly Disagree
Disagree
Undecided
Agree
Strongly Agree
How much has your confidence increased in the following areas as a result of attending this conference?
Demonstrate appropriate interpretation of cardiovascular guidelines and diagnostic strategies needed in daily practice.
None
Minimal
Moderate
Great
N/A
Employ evidence-based strategies in the treatment of patients with heart failure
None
Minimal
Moderate
Great
N/A
Identify prevention strategies for cardiovascular disease including CV risk assessment and risk reduction strategies
None
Minimal
Moderate
Great
N/A
Apply the latest evidence to the evaluation, medical management and surgical treatment of patients with valvular heart disease.
None
Minimal
Moderate
Great
N/A
Evaluate current treatment strategies in the investigation and management of coronary artery disease.
None
Minimal
Moderate
Great
N/A
Identify best practices for the management of patients with atrial and ventricular arrhythmias
None
Minimal
Moderate
Great
N/A
Demonstrate improved ECG interpretation skills
None
Minimal
Moderate
Great
N/A
After this course, what is one thing you will do differently in your practice to improve patient outcomes?
What topics would you like to see offered during future ACC Middle East Conferences?
Please provide any overall general feedback about your experience of this conference.
Was there any commercial bias during the conference? If so please provide details on the speaker and/or session
CASE-BASED QUESTIONS
The following questions are designed to help you and the faculty gauge current understanding of concepts in cardiovascular care that were addressed in the course. Individual scores are not provided to the faculty. Responses are confidential and only reported in aggregate.
A 67 year old man presents for recommendations regarding lipid management. He has a history of PCI of the RCA following NSTEMI 2 years ago. He has known diabetes and hypertension. He is tolerating therapy with atorvastatin 80 mg daily. His current lipid panel shows: Total cholesterol: 151 mg/dL, HDL cholesterol: 40 mg/dL, LDL cholesterol: 68 mg/dL, Triglycerides: 217 mg/dL. Based on the results of the REDUCE-IT trial, which ONE of the following is CORRECT regarding the expectations for this patient with the addition of icosapent ethyl to statin therapy?
*
The addition of icosapent ethyl should be avoided due to an increased risk of major bleeding.
The addition of icosapent ethyl is associated with a relative risk reduction of 21% for new onset atrial fibrillation.
The addition of icosapent ethyl is associated with 25% reduction in CV death, MI, stroke, revascularization, and unstable angina.
The addition of icosapent ethyl should be avoided due to an increased risk of worsening glycemic control in patients with diabetes.
Which of the following electrocardiographic criteria has the highest sensitivity and specificity to determine if a wide complex tachycardia is most likely ventricular tachycardia?
*
Absence of an RS complex in all precordial leads
A-V dissociation
Longest R to S interval > 100ms in any precordial lead
Presence of an initial r or q wave > 40 ms in aVR
R wave peak time > 50 ms in lead DII
According to the 2019 ACC/AHA Primary Prevention Guidelines, which ONE of the following is CORRECT regarding the use of aspirin?
*
Aspirin 325 mg daily should be considered for patients with 10-year ASCVD risk of >7.5 to 19.9% who are not at increased risk of bleeding.
Aspirin 75-100 mg daily might be considered among select adults 40 to 70 years of age who are at higher ASCVD risk but not at increased bleeding risk.
Aspirin 75-100 mg daily should be administered for the primary prevention of stroke among adults >70 years of age.
Low-dose aspirin (75-100 mg orally daily) is not associated with an increased bleeding risk when compared to full dose aspirin (325 mg daily) for the primary prevention of ASCVD.
Regarding the end diameter of systole as a surgical indicator in asymptomatic aortic regurgitation:
*
The 55mm cut-off point is the most robust mortality indicator
The 25 mm / m2 cut-off point is the most robust mortality indicator
The 50mm cut-off point is the most robust mortality indicator
The 20 mm / m2 cut-off point is the most robust mortality indicator
A 70-year-old woman presents to your clinic for evaluation of her progressive lower extremity edema and dyspnea on exertion. Her medical history includes hypertension, diabetes, and chronic kidney disease. She is on lisinopril, hydrochlorothiazide, and insulin. Transthoracic echo reveals left ventricular (LV) ejection fraction of 65%, moderate concentric LV hypertrophy, normal valvular function, pulmonary artery systolic pressure of 45 mm Hg, and E/e' ratio of 18. Which the following therapies have been proven effective to reduce her mortality from her heart failure with preserved ejection fraction (HFpEF)?
*
Diuretics
No therapy reduces mortality
Spironolactone
Beta-blockers
ACE inhibitors
A 60-year-old man with a history of Type 2 IDDM, hypertension, and hyperlipidemia presents to emergency department 2 hours after onset of typical chest pain and dyspnea. The patient appears diaphoretic, pale and anxious. On initial evaluation BP: 80/60, HR: 120bpm, and RR: 24. The EKG shows ST segment elevation in the anterior leads. The patient is taken to the catheterization lab for an emergent PCI. Which of the following statements regarding hemodynamic support for this patient is correct according to the ACC/AHA guidelines?
*
IABP counter-pulsation is recommended in every STEMI case
IABP counter-pulsation is recommended in every STEMI case complicated with cardiogenic shock
Percutaneous LV support devices are recommended in every STEMI case complicated with shock
IABP counter-pulsation is recommended for patients with STEMI complicated by cardiogenic shock who do not quickly stabilize with pharmacological therapy.
Percutaneous LV support devices are recommended for patients with STEMI complicated by cardiogenic shock who do not quickly stabilize with pharmacological therapy.
You are advising your patient with HFrEF and atrial fibrillation regarding the choice between atrial fibrillation ablation versus medical therapy. Based on CASTLE-AF data, and the 2019 ACC Atrial Fibrillation Guideline, you will inform them that AF ablation is a reasonable option that may:
*
Reduce their risk of stroke and death.
Reduce their risk of inappropriate ICD shocks and death.
Reduce their risk of death and hospitalization for heart failure.
Reduce their risk of stroke and hospitalization for heart failure.
Please enter your personal details
Name
*
First Name
Last Name
Email
*
Please insert the final four digits in your Registration ID#
*
e.g. If your ID is "ECS2019-1111", please enter only "1111" into this box.